Study: NCT02735707

Intervention type: OTHER
Group type: OTHER
Intervention: No antiplatelet
Description: No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12 inhibitor
Description: Site-selected P2Y12 inhibitor:~* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: OTHER
Group type: OTHER
Intervention: No simvastatin
Description: No simvastatin intended to be active against COVID-19 is to be administered~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Eritoran
Description: Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinician-preferred mechanical ventilation strategy
Description: Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protocolised mechanical ventilation strategy
Description: Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.

Intervention type: OTHER
Group type: OTHER
Intervention: No renin-angiotensin system inhibitor
Description: No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin converting enzyme inhibitor
Description: Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin Receptor Blockers
Description: Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: ARB + DMX-200
Description: Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed.

Intervention type: OTHER
Group type: OTHER
Intervention: No cysteamine
Description: No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Cysteamine
Description: Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Fixed-duration dexamethasone
Description: 6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.

Intervention type: DRUG
Group type: OTHER
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil administered on days 1 and 4 post-randomisation.

Intervention type: DRUG
Group type: OTHER
Intervention: Five-days oseltamivir + baloxavir marboxil
Description: Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

Intervention type: DRUG
Group type: OTHER
Intervention: Ten-days oseltamivir + baloxavir marboxil
Description: Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.